Recap: Catalent Q1 Earnings
Catalent (NYSE:CTLT) reported its Q1 earnings results on Wednesday, November 15, 2023 at 06:59 AM. Here’s what investors…
Preview: Catalent’s Earnings
Catalent (NYSE:CTLT) is set to give its latest quarterly earnings report on Wednesday, 2023-11-15. Here’s what investors need…
What’s Going On With Biotech Contract Service Firm Catalent Stock Today?
Catalent Inc (NYSE: CTLT) shares are trading lower due to its significant exposure to Sarepta Therapeutics Inc (NASDAQ: SRPT) on the back of disappointing data from a pivotal gene therapy trial.
Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session
Gainers
SciSparc Ltd. (NASDAQ: SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian patent office for its patent application for Combination of Opioids and N-Acylethanolamines for pain treatment.
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers TransCode Therapeutics (NASDAQ:RNAZ) shares increased by 16.7% to $0.42 during Monday’s after-market session. Today’s trading volume for…
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
Weight-Loss Drug Boom Has Another Ripple Effect – Rapid Growth Expected In Fill-Finish Market
Contract drug manufacturers are investing billions of dollars in expanding or constructing facilities that fill the injection pens used for weight-loss drugs like Novo Nordisk A/S's (NYSE: NVO) Wegovy.
Analyst Ratings for Catalent
Over the past 3 months, 10 analysts have published their opinion on Catalent (NYSE:CTLT) stock. These analysts are…
Melt Pharmaceuticals Announces Exclusive Development And License Agreement With Catalent For Its Zydis Fast-Dissolve Technology For Use In MELT-300 For Needle- And Opioid-Free Procedural Sedation
Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced it recently entered into an exclusive development and license agreement with
Benzinga’s Top Ratings Upgrades, Downgrades For September 5, 2023
Upgrades For Belden Inc (NYSE:BDC), Goldman Sachs upgraded the previous rating of Neutral to Buy. Belden earned $1.91…